Drug Trial Radar · NCT05898399
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
181
Planned (sponsor's estimate)
Start
Jun 30, 2023
Primary completion
Jun 30, 2028
Study completion Sep 30, 2028
Sponsor
- Lead sponsor
- Artios Pharma LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.
Conditions
- Advanced Solid Tumor
- Metastatic Solid Tumor
Interventions
ART6043Drug
ART6043 will be given orally.
OlaparibDrug
Olaparib will be given orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of participants with Dose Limiting Toxicities (DLTs)Time frame: From first dose of study treatment until the end of Cycle 1 (each cycle is 21-days)
- Part B2: Progression free survival (PFS)Time frame: Until disease progression (Upto 3.7 years).
Locations
27 sites in 3 countries. Site status is shown where the registry gives one.
South Texas Accelerated Research Therapeutics (START) - Midwest
Grand Rapids, Michigan · Active not recruiting
Memorial Sloan-Kettering Cancer Center (MSKCC)
New York, New York · Active not recruiting
Stephenson Cancer Center - Oncology
Oklahoma City, Oklahoma · Active not recruiting
Jefferson University Hospitals - Kimmel Cancer Center
Philadelphia, Pennsylvania · Active not recruiting
SCRI oncology partners
Nashville, Tennessee · Completed
Mary Crowley Cancer Center - Clinic
Dallas, Texas · Completed
The University of Texas - MD Anderson Cancer Center
Houston, Texas · Active not recruiting
Complejo Hospitalario Universitario A Coruña CHUAC
A Coruña, Spain · Recruiting
Instituto Valenciano de Oncologia-IVO
Bàguena, Spain · Recruiting
Hospital Universitario de Jerez de la Frontera
Cadiz, Spain · Recruiting
Hospital Universitario de Canarias
Canara, Spain · Recruiting
Hospital Universitario de Jaen
Jaén, Spain · Recruiting
Hospital General Universitario Gregorio Marañon
Madrid, Spain · Recruiting
Hospital Universitario Virgen de la Victoria
Málaga, Spain · Recruiting
Hospital Clinico Universitario Virgen de la Arrixaca
Murcia, Spain · Recruiting
Hospital Universitario Virgen del Rocio
Seville, Spain · Recruiting
Hospital Universitario Virgen Macarena
Seville, Spain · Recruiting
Hospital Clinico Universitario de Valencia
Valencia, Spain · Recruiting
Hospital Clinico Universitario Lozano Blesa
Zaragoza, Spain · Recruiting
Hospital Universitario Clínico San Cecilio
Granada, Andalusia, Spain · Recruiting
Hospital Clínico Universitario de Valladolid
Valladolid, Castille and León, Spain · Recruiting
Hospital de la Santa Creu i Sant Pau
Barcelona, Catalonia, Spain · Recruiting
Hospital San Pedro de Alcántara
Cáceres, Extremadura, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Madrid, Spain · Recruiting
Hospital Clinico San Carlos
San Carlos, Madrid, Spain · Recruiting
University College London
London, United Kingdom · Recruiting
The Christie
Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.